Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition
文献类型：期刊论文
| 作者 | Liu, Can1,2,3; Zeng, Yan2; Dai, Long-Hai2; Cai, Tian-Yu1; Zhu, Yue-Ming2; Dou, De-Quan1; Ma, Lan-Qing1,3; Sun, Yuan-Xia2 |
| 刊名 | AMERICAN JOURNAL OF CANCER RESEARCH
 |
| 出版日期 | 2015 |
| 卷号 | 5期号:4页码:1308-+ |
| 关键词 | Mogrosides mogrol apoptosis ERK1/2 STAT3 |
| 英文摘要 | Unlike solid tumors, the primary strategy for leukemia treatment is chemotherapy. However, leukemia chemotherapy is associated with adverse drug effects and drug resistance. Therefore, it is imperative to identify novel agents that effectively treat leukemia while minimizing adverse effects. The Raf/MEK/extracellular regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) pathways have been implicated in leukemia carcinogenesis, and provide novel molecular targets for therapeutic intervention in cancer. Mogrol, a biometabolite of mogrosides found in Siraitia grosvenorii, has exhibited anti-cancer activities; however, the underlying mechanism of this effect remains unclear. To clarify its anti-cancer activity and mechanism of action, we treated K562 leukemia cells with mogrol. Mogrol suppressed leukemia cell growth via inhibition of the ERK1/2 and STAT3 pathways, in particular, through the suppression of p-ERK1/2 and p-STAT3. Inhibition of these pathways suppressed Bcl-2 expression, thereby inducing K562 cell apoptosis. Furthermore, mogrol enhanced p21 expression, resulting in G0/G1 cell cycle arrest. The findings provide new perspectives regarding the role of mogrol in leukemia treatment. |
| WOS标题词 | Science & Technology ; Life Sciences & Biomedicine |
| 类目[WOS] | Oncology |
| 研究领域[WOS] | Oncology |
| 关键词[WOS] | SIGNALING INDUCES APOPTOSIS ; CYCLIN-DEPENDENT KINASES ; CANCER-CELLS ; K562 CELLS ; CONSTITUTIVE ACTIVATION ; MOMORDICA-GROSVENORI ; CARCINOMA CELLS ; S-PHASE ; BCL-2 ; INTERVENTION |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000356495900004 |
| 源URL | [http://124.16.173.210/handle/834782/1496]  |
| 专题 | 天津工业生物技术研究所_功能糖与天然活性物质研究组 孙媛霞 _期刊论文 |
| 作者单位 | 1.Beijing Agr Univ, Beijing 102206, Peoples R China 2.Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Natl Engn Lab Ind Enzymes, Tianjin 300308, Peoples R China 3.Beijing Agr Univ, Minist Agr PR China, Key Lab Urban Agr North, Beijing 102206, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, Can,Zeng, Yan,Dai, Long-Hai,et al. Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition[J]. AMERICAN JOURNAL OF CANCER RESEARCH,2015,5(4):1308-+. |
| APA | Liu, Can.,Zeng, Yan.,Dai, Long-Hai.,Cai, Tian-Yu.,Zhu, Yue-Ming.,...&Sun, Yuan-Xia.(2015).Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition.AMERICAN JOURNAL OF CANCER RESEARCH,5(4),1308-+. |
| MLA | Liu, Can,et al."Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition".AMERICAN JOURNAL OF CANCER RESEARCH 5.4(2015):1308-+. |
入库方式： OAI收割
来源：天津工业生物技术研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。